Exenatide vs Pramlintide
Research Verdict
Neither compound has a universal evidence advantage. Both peptides serve distinct research goals with comparable evidence; choose by target mechanism.
Quick Answers
Which is better, Exenatide or Pramlintide?
Neither compound has a universal evidence advantage. Both peptides serve distinct research goals with comparable evidence; choose by target mechanism.
What is the key difference between Exenatide and Pramlintide?
Pramlintide replaces amylin (co-secreted with insulin, deficient in diabetes) to slow gastric emptying and suppress glucagon; exenatide mimics GLP-1 to enhance glucose-dependent insulin secretion - complementary mechanisms that have been studied in combination.
Evidence Comparison
Exenatide: FDA approved GLP-1RA, EXSCEL CVOT (neutral), substantial Phase 3 program. Pramlintide (Symlin): FDA approved amylin analog, smaller Phase 3 program, no CVOT. Exenatide has broader evidence and more widespread clinical adoption.
Evidence Context Favoring Exenatide
GLP-1-based glycemic control with potential CV benefit and weight loss as co-primary endpoints.
Evidence Context Favoring Pramlintide
Postprandial glucose control in insulin-using patients where amylin replacement is the mechanistic target, or combination therapy research.
Side-by-Side Snapshot
| Evidence grade | Exenatide: Level A Pramlintide: Level A |
|---|---|
| Research status | Exenatide: FDA Approved Pramlintide: FDA Approved |
| Primary category | Exenatide: Weight Loss & Metabolic Pramlintide: Weight Loss & Metabolic |
| Cited studies | Exenatide: 3 Pramlintide: 3 |